Oruka Therapeutics, Inc. Business Combination, Acquisition Related Costs
Oruka Therapeutics, Inc. (ORKA) reported Business Combination, Acquisition Related Costs of $5.47 million for the 147-month period ending 2014-03-31, per its 10-Q filed 2014-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2014-05-13
- Oruka Therapeutics, Inc. business combination, acquisition related costs for the quarter ending 2013-12-31 was $0.00.
- Oruka Therapeutics, Inc. business combination, acquisition related costs for the quarter ending 2013-03-31 was $0.00.
- Oruka Therapeutics, Inc. business combination, acquisition related costs for the quarter ending 2012-12-31 was $0.00.
- Oruka Therapeutics, Inc. business combination, acquisition related costs for the quarter ending 2012-09-30 was $0.00.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month | Business Combination, Acquisition Related Costs 114 month | Business Combination, Acquisition Related Costs 117 month | Business Combination, Acquisition Related Costs 120 month | Business Combination, Acquisition Related Costs 123 month | Business Combination, Acquisition Related Costs 126 month | Business Combination, Acquisition Related Costs 129 month | Business Combination, Acquisition Related Costs 132 month | Business Combination, Acquisition Related Costs 135 month | Business Combination, Acquisition Related Costs 138 month | Business Combination, Acquisition Related Costs 141 month | Business Combination, Acquisition Related Costs 144 month | Business Combination, Acquisition Related Costs 147 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $5.47M 10-Q · filed 2014-05-13 | |||||||||||||||
| 2013-12-31 | $0.00 derived: 10-K 144 month − 10-Q 141 month · filed 2014-03-20 | $5.47M 10-K · filed 2014-03-20 | ||||||||||||||
| 2013-09-30 | $5.47M 10-Q · filed 2013-11-13 | |||||||||||||||
| 2013-06-30 | $5.47M 10-Q · filed 2013-08-13 | |||||||||||||||
| 2013-03-31 | $0.00 derived: 10-Q 135 month − 10-K 132 month · filed 2013-05-13 | $0.00 derived: sum of 2 quarters · filed 2013-05-13 | $0.00 derived: sum of 3 quarters · filed 2013-05-13 | $0.00 derived: sum of 4 quarters · filed 2013-05-13 | $5.47M 10-Q · filed 2013-05-13 | |||||||||||
| 2012-12-31 | $0.00 derived: 10-K 132 month − 10-Q 129 month · filed 2013-03-21 | $0.00 derived: sum of 2 quarters · filed 2013-03-21 | $0.00 derived: sum of 3 quarters · filed 2013-03-21 | $0.00 derived: sum of 4 quarters · filed 2013-03-21 | $5.47M 10-K · filed 2013-03-21 | |||||||||||
| 2012-09-30 | $0.00 derived: 10-Q 129 month − 10-Q 126 month · filed 2012-11-13 | $0.00 derived: sum of 2 quarters · filed 2012-11-13 | $0.00 derived: sum of 3 quarters · filed 2012-11-13 | $0.00 derived: sum of 4 quarters · filed 2012-11-13 | $5.47M 10-Q · filed 2012-11-13 | |||||||||||
| 2012-06-30 | $0.00 derived: 10-Q 126 month − 10-Q 123 month · filed 2012-08-13 | $0.00 derived: sum of 2 quarters · filed 2012-08-13 | $0.00 derived: sum of 3 quarters · filed 2012-08-13 | $0.00 derived: sum of 4 quarters · filed 2012-08-13 | $5.47M 10-Q · filed 2012-08-13 | |||||||||||
| 2012-03-31 | $0.00 derived: 10-Q 123 month − 10-K 120 month · filed 2012-05-14 | $0.00 derived: sum of 2 quarters · filed 2012-05-14 | $0.00 derived: sum of 3 quarters · filed 2012-05-14 | $5.47M 10-Q · filed 2012-05-14 | ||||||||||||
| 2011-12-31 | $0.00 derived: 10-K 120 month − 10-Q 117 month · filed 2012-03-27 | $0.00 derived: sum of 2 quarters · filed 2012-03-27 | $5.47M 10-K · filed 2012-03-27 | |||||||||||||
| 2011-09-30 | $0.00 derived: 10-Q 117 month − 10-Q 114 month · filed 2011-11-14 | $5.47M 10-Q · filed 2011-11-14 | ||||||||||||||
| 2011-06-30 | $5.47M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |